Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric carboxymaltose in iron-deficient patients after recent myocardial infarction
2024-517206-28-00Phase 4Authorised
- Sponsor
- Wroclaw Medical University
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in myocardial infarction (MI), iron deficiency anemia (IDA) and heart failure (HF) comparing Ferric carboxymaltose with Placebo (0.9% sodium chloride) (2 arms). Primary endpoints: Time to all-cause death, Number of heart failure events and 3 more. Planned start Nov 2024; status: authorised.
02
Drugs
ferric carboxymaltose
03
Conditions
myocardial infarction (MI)iron deficiency anemia (IDA)heart failure (HF)
Beyond the preview
Go deeper on 2024-517206-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517206-28-00.